These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 19810872)
1. Neuroprotection in Parkinson's disease: love story or mission impossible? Linazasoro GJ Expert Rev Neurother; 2002 May; 2(3):403-16. PubMed ID: 19810872 [TBL] [Abstract][Full Text] [Related]
2. Management of Parkinson's disease a review of current and new therapies. Mendis T; Suchowersky O; Lang A; Gauthier S Can J Neurol Sci; 1999 May; 26(2):89-103. PubMed ID: 10352867 [TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068 [TBL] [Abstract][Full Text] [Related]
4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease. Novikova L; Garris BL; Garris DR; Lau YS Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572 [TBL] [Abstract][Full Text] [Related]
5. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092 [TBL] [Abstract][Full Text] [Related]
8. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia. Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733 [TBL] [Abstract][Full Text] [Related]
9. Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications. Mouradian MM; Chase TN Exp Neurol; 1997 Mar; 144(1):51-7. PubMed ID: 9126152 [TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease: diagnosis and treatment. Rao SS; Hofmann LA; Shakil A Am Fam Physician; 2006 Dec; 74(12):2046-54. PubMed ID: 17186710 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. Watanabe Y; Himeda T; Araki T Med Sci Monit; 2005 Jan; 11(1):RA17-23. PubMed ID: 15614202 [TBL] [Abstract][Full Text] [Related]
13. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Kondo T J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060 [TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease in 1984: an update. Lang AE; Blair RD Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779 [TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study. Shin JY; Park HJ; Ahn YH; Lee PH J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187 [TBL] [Abstract][Full Text] [Related]
16. Heredity in Parkinson's disease: new findings. Lev N; Melamed E Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638 [TBL] [Abstract][Full Text] [Related]
17. Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Hille CJ; Fox SH; Maneuf YP; Crossman AR; Brotchie JM Exp Neurol; 2001 Nov; 172(1):189-98. PubMed ID: 11681851 [TBL] [Abstract][Full Text] [Related]
18. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Jenner P; Marsden CD J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760 [TBL] [Abstract][Full Text] [Related]
19. Treatment of Parkinson's disease: levodopa as the first choice. Katzenschlager R; Lees AJ J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059 [TBL] [Abstract][Full Text] [Related]